{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T20:39:09Z","timestamp":1768423149733,"version":"3.49.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-04093-2","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:16:18Z","timestamp":1765430178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methylated CfDNA may distinguish between high- and intermediate-risk uveal melanoma: a pilot study"],"prefix":"10.1186","volume":"26","author":[{"given":"Mike","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00ebl P.","family":"de Bruyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben G.","family":"Boers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron B.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daan M.","family":"Hazelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Makrodimitris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim B.","family":"Boers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanda","family":"Vaarwater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald O.B.","family":"de Keizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Verdijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole C.","family":"Naus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dion","family":"Paridaens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia M.","family":"Wilting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elin S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfred F.J.","family":"van IJcken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"Gribnau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"de Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"Brosens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emine","family":"Kili\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Rotterdam Ocular Melanoma Studygroup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"13","key":"4093_CR1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.13.45","volume":"64","author":"M Wu","year":"2023","unstructured":"Wu M, Yavuzyigitoglu S, Brosens E, Ramdas WD, Kilic E, Rotterdam Ocular Melanoma Study G. Worldwide incidence of ocular melanoma and correlation with pigmentation-related risk factors. Invest Ophthalmol Vis Sci. 2023;64(13):45. https:\/\/doi.org\/10.1167\/iovs.64.13.45.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"0","key":"4093_CR2","doi-asserted-by":"publisher","first-page":"37897","DOI":"10.1167\/iovs.0.0.37897","volume":"0","author":"DP De Bruyn","year":"2024","unstructured":"De Bruyn DP, Van Poppelen NM, Brands T, et al. Evaluation of Circulating tumor DNA as a liquid biomarker in uveal melanoma. Investigative Ophthalmol & Visual Science 2024;Invest Ophthalmol Vis Sci. 2024;0(0):37897. https:\/\/doi.org\/10.1167\/iovs.0.0.37897.","journal-title":"Investigative Ophthalmol & Visual Science 2024;Invest Ophthalmol Vis Sci"},{"key":"4093_CR3","unstructured":"Kivel\u00e4 T, Simpson RE, Grossniklaus HE et al. Uveal melanoma. In: AJCC Cancer Staging Manual. 8th ed. New York, NY. 2016;805\u2013817."},{"issue":"1","key":"4093_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-0158-0","volume":"6","author":"MJ Jager","year":"2020","unstructured":"Jager MJ, Shields CL, Cebulla CM, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):1\u201325.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"4093_CR5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","volume":"123","author":"S Yavuzyigitoglu","year":"2016","unstructured":"Yavuzyigitoglu S, Koopmans AE, Verdijk RM, et al. Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases. Ophthalmology. 2016;123(5):1118\u201328.","journal-title":"Ophthalmology"},{"issue":"2","key":"4093_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020506","volume":"10","author":"DP de Bruyn","year":"2022","unstructured":"de Bruyn DP, Beasley AB, Verdijk RM, et al. Is tissue still the issue? The promise of liquid biopsy in uveal melanoma. Biomedicines. 2022;10(2):506. https:\/\/doi.org\/10.3390\/biomedicines10020506.","journal-title":"Biomedicines"},{"issue":"8","key":"4093_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/aos.13823","volume":"96","author":"JGM van Beek","year":"2018","unstructured":"van Beek JGM, Buitendijk GHS, Timman R, et al. Quality of life: fractionated stereotactic radiotherapy versus enucleation treatment in uveal melanoma patients. Acta Ophthalmol. 2018;96(8):841\u20138. https:\/\/doi.org\/10.1111\/aos.13823.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"4093_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/sj.eye.6702276","volume":"21","author":"J Khan","year":"2007","unstructured":"Khan J, Damato BE. Accuracy of choroidal melanoma diagnosis by general ophthalmologists: a prospective study. Eye (Lond). 2007;21(5):595\u20137. https:\/\/doi.org\/10.1038\/sj.eye.6702276.","journal-title":"Eye (Lond)"},{"issue":"8","key":"4093_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/bjophthalmol-2017-310361","volume":"101","author":"M Angi","year":"2017","unstructured":"Angi M, Kalirai H, Taktak A, et al. Prognostic biopsy of choroidal melanoma: an optimised surgical and laboratory approach. Br J Ophthalmol Aug. 2017;101(8):1143\u20136. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310361.","journal-title":"Br J Ophthalmol Aug."},{"issue":"1","key":"4093_CR10","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.1.15","volume":"64","author":"AN Chao","year":"2023","unstructured":"Chao AN, Rose K, Racher H, Altomare F, Krema H. Cytogenetic abnormalities for predicting the risk of metastases in choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci. 2023;64(1):15. https:\/\/doi.org\/10.1167\/iovs.64.1.15.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"4093_CR11","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1167\/iovs.13-12195","volume":"54","author":"KG Ewens","year":"2013","unstructured":"Ewens KG, Kanetsky PA, Richards-Yutz J, et al. Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome. Invest Ophthalmol Vis Sci. 2013;54(8):5721\u20139. https:\/\/doi.org\/10.1167\/iovs.13-12195.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4093_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.100800","volume":"75","author":"KN Smit","year":"2020","unstructured":"Smit KN, Jager MJ, de Klein A, Kili\u04ab E. Uveal melanoma: towards a molecular understanding. Prog Retin Eye Res. 2020;75:100800.","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"4093_CR13","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.3390\/cancers13071740","volume":"13","author":"JJ Park","year":"2021","unstructured":"Park JJ, Diefenbach RJ, Byrne N, et al. Circulating tumor DNA reflects uveal melanoma responses to protein kinase C inhibition. Cancers. 2021;13(7):1740.","journal-title":"Cancers"},{"issue":"4","key":"4093_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ophtha.2016.10.039","volume":"124","author":"S Yavuzyigitoglu","year":"2017","unstructured":"Yavuzyigitoglu S, Drabarek W, Smit KN, et al. Correlation of gene mutation status with copy number profile in uveal melanoma. Ophthalmology Apr. 2017;124(4):573\u20135. https:\/\/doi.org\/10.1016\/j.ophtha.2016.10.039.","journal-title":"Ophthalmology Apr"},{"issue":"8","key":"4093_CR15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ng.2674","volume":"45","author":"M Martin","year":"2013","unstructured":"Martin M, Ma\u00dfh\u00f6fer L, Temming P, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013;45(8):933\u20136.","journal-title":"Nat Genet"},{"issue":"37","key":"4093_CR16","doi-asserted-by":"publisher","first-page":"E2424","DOI":"10.1073\/pnas.1207846109","volume":"109","author":"S Lee","year":"2012","unstructured":"Lee S, Liu B, Lee S, Huang S-X, Shen B, Qian S-B. Global mapping of translation initiation sites in mammalian cells at single-nucleotide resolution. Proc Natl Acad Sci. 2012;109(37):E2424\u201332. https:\/\/doi.org\/10.1073\/pnas.1207846109.","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"4093_CR17","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1167\/iovs.18-24818","volume":"60","author":"W Drabarek","year":"2019","unstructured":"Drabarek W, Yavuzyigitoglu S, Obulkasim A, et al. Multi-modality analysis improves survival prediction in enucleated uveal melanoma patients. Invest Ophthalmol Vis Sci. 2019;60(10):3595\u2013605.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"4093_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.celrep.2018.01.088","volume":"23","author":"M Seiler","year":"2018","unstructured":"Seiler M, Peng S, Agrawal AA, et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 2018;23(1):282-296.e4. https:\/\/doi.org\/10.1016\/j.celrep.2018.01.088.","journal-title":"Cell Rep"},{"issue":"10","key":"4093_CR19","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jamaophthalmol.2018.2986","volume":"136","author":"E Szalai","year":"2018","unstructured":"Szalai E, Jiang Y, van Poppelen NM, et al. Association of uveal melanoma metastatic rate with stochastic mutation rate and type of mutation. JAMA Ophthalmol. 2018;136(10):1115\u201320. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.2986.","journal-title":"JAMA Ophthalmol"},{"key":"4093_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00279","author":"A Beasley","year":"2018","unstructured":"Beasley A, Isaacs T, Khattak MA, et al. Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma. JCO Precis Oncol. 2018. https:\/\/doi.org\/10.1200\/PO.17.00279.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"4093_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01984-w","volume":"40","author":"P Bustamante","year":"2021","unstructured":"Bustamante P, Tsering T, Coblentz J, et al. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma. J Exp Clin Cancer Res. 2021;40(1):196. https:\/\/doi.org\/10.1186\/s13046-021-01984-w.","journal-title":"J Exp Clin Cancer Res"},{"key":"4093_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065077","author":"DP de Bruyn","year":"2023","unstructured":"de Bruyn DP, Bongaerts M, Bonte R, et al. Uveal melanoma patients have a distinct metabolic phenotype in peripheral blood. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24065077.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4093_CR23","first-page":"1947","volume":"8","author":"L Li","year":"2018","unstructured":"Li L, Zhang J, Jiang X, Li Q. Promising clinical application of ctdna in evaluating immunotherapy efficacy. Am J Cancer Res. 2018;8(10):1947\u201356.","journal-title":"Am J Cancer Res"},{"key":"4093_CR24","doi-asserted-by":"publisher","unstructured":"Beasley AB, de Bruyn DP, Calapre L, et al. Detection of metastases using circulating tumour DNA in uveal melanoma. J Cancer Res Clin Oncol. 2023;149(16):14953\u201363. https:\/\/doi.org\/10.1007\/s00432-023-05271-3.","DOI":"10.1007\/s00432-023-05271-3"},{"issue":"6378","key":"4093_CR25","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926\u201330. https:\/\/doi.org\/10.1126\/science.aar3247.","journal-title":"Science"},{"issue":"9","key":"4093_CR26","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985\u201390. https:\/\/doi.org\/10.1038\/nm.1789.","journal-title":"Nat Med"},{"issue":"10","key":"4093_CR27","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1158\/2159-8290.CD-21-1252","volume":"13","author":"AK Mattox","year":"2023","unstructured":"Mattox AK, Douville C, Wang Y, et al. The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer. Cancer Discov. 2023;13(10):2166\u201379. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1252.","journal-title":"Cancer Discov"},{"issue":"1","key":"4093_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8(1):1324. https:\/\/doi.org\/10.1038\/s41467-017-00965-y.","journal-title":"Nat Commun"},{"issue":"8","key":"4093_CR29","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1093\/annonc\/mdx212","volume":"28","author":"L Cabel","year":"2017","unstructured":"Cabel L, Riva F, Servois V, et al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol. 2017;28(8):1996\u20132001. https:\/\/doi.org\/10.1093\/annonc\/mdx212.","journal-title":"Ann Oncol"},{"issue":"5","key":"4093_CR30","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/ijc.28436","volume":"134","author":"FC Bidard","year":"2014","unstructured":"Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer. 2014;134(5):1207\u201313. https:\/\/doi.org\/10.1002\/ijc.28436.","journal-title":"Int J Cancer"},{"issue":"5","key":"4093_CR31","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.molmed.2020.12.011","volume":"27","author":"H Luo","year":"2021","unstructured":"Luo H, Wei W, Ye Z, Zheng J, Xu R-h. Liquid biopsy of methylation biomarkers in cell-free DNA. Trends Mol Med. 2021;27(5):482\u2013500. https:\/\/doi.org\/10.1016\/j.molmed.2020.12.011.","journal-title":"Trends Mol Med"},{"issue":"1","key":"4093_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/s0168-9525(98)01636-9","volume":"15","author":"PA Jones","year":"1999","unstructured":"Jones PA. The DNA methylation paradox. Trends Genet. 1999;15(1):34\u20137. https:\/\/doi.org\/10.1016\/s0168-9525(98)01636-9.","journal-title":"Trends Genet"},{"issue":"1","key":"4093_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01382-9","volume":"14","author":"Q Wang","year":"2022","unstructured":"Wang Q, Xiong F, Wu G, et al. Gene body methylation in cancer: molecular mechanisms and clinical applications. Clin Epigenetics. 2022;14(1):154. https:\/\/doi.org\/10.1186\/s13148-022-01382-9.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"4093_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05550-5","volume":"9","author":"M Arechederra","year":"2018","unstructured":"Arechederra M, Daian F, Yim A, et al. Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer. Nat Commun. 2018;9(1):3164. https:\/\/doi.org\/10.1038\/s41467-018-05550-5.","journal-title":"Nat Commun"},{"issue":"11","key":"4093_CR35","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37(11):1012\u201327. https:\/\/doi.org\/10.1016\/j.tig.2021.05.002.","journal-title":"Trends Genet"},{"issue":"1","key":"4093_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47195-7","volume":"15","author":"A-M Conway","year":"2024","unstructured":"Conway A-M, Pearce SP, Clipson A, et al. A cfdna methylation-based tissue-of-origin classifier for cancers of unknown primary. Nat Commun. 2024;15(1):3292. https:\/\/doi.org\/10.1038\/s41467-024-47195-7.","journal-title":"Nat Commun"},{"issue":"1","key":"4093_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03964-8","volume":"12","author":"KN Smit","year":"2022","unstructured":"Smit KN, Boers R, Vaarwater J, et al. Genome-wide aberrant methylation in primary metastatic UM and their matched metastases. Sci Rep. 2022;12(1):42. https:\/\/doi.org\/10.1038\/s41598-021-03964-8.","journal-title":"Sci Rep"},{"issue":"1","key":"4093_CR38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1101\/gr.222885.117","volume":"28","author":"R Boers","year":"2018","unstructured":"Boers R, Boers J, de Hoon B, et al. Genome-wide DNA methylation profiling using the methylation-dependent restriction enzyme LpnPI. Genome Res. 2018;28(1):88\u201399. https:\/\/doi.org\/10.1101\/gr.222885.117.","journal-title":"Genome Res"},{"issue":"2","key":"4093_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","volume":"32","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Shih J, Yau C, et al. Integrative analysis identifies four molecular and clinical subsets in Uveal Melanoma. Cancer Cell. 2017;32(2):204-220 e15. https:\/\/doi.org\/10.1016\/j.ccell.2017.07.003.","journal-title":"Cancer Cell"},{"issue":"1","key":"4093_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01177-4","volume":"13","author":"T Deger","year":"2021","unstructured":"Deger T, Boers RG, de Weerd V, et al. High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments. Clin Epigenetics. 2021;13(1):196. https:\/\/doi.org\/10.1186\/s13148-021-01177-4.","journal-title":"Clin Epigenetics"},{"issue":"18","key":"4093_CR41","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.clinbiochem.2016.03.012","volume":"49","author":"Q Kang","year":"2016","unstructured":"Kang Q, Henry NL, Paoletti C, et al. Comparative analysis of circulating tumor DNA stability in K(3)EDTA, Streck, and CellSave blood collection tubes. Clin Biochem. 2016;49(18):1354\u201360. https:\/\/doi.org\/10.1016\/j.clinbiochem.2016.03.012.","journal-title":"Clin Biochem"},{"issue":"5","key":"4093_CR42","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/modpathol.2017.187","volume":"31","author":"KN Smit","year":"2018","unstructured":"Smit KN, van Poppelen NM, Vaarwater J, et al. Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma. Mod Pathol. 2018;31(5):763\u201371. https:\/\/doi.org\/10.1038\/modpathol.2017.187.","journal-title":"Mod Pathol"},{"issue":"10","key":"4093_CR43","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/modpathol.2014.43","volume":"27","author":"AE Koopmans","year":"2014","unstructured":"Koopmans AE, Verdijk RM, Brouwer RW, et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol. 2014;27(10):1321\u201330. https:\/\/doi.org\/10.1038\/modpathol.2014.43.","journal-title":"Mod Pathol"},{"issue":"4","key":"4093_CR44","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357\u20139. https:\/\/doi.org\/10.1038\/nmeth.1923.","journal-title":"Nat Methods"},{"key":"4093_CR45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Yoav Benjamini","year":"1995","unstructured":"Benjamini Yoav, Yosef H. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statis Soc Ser B (Methodol). 1995;57:289\u2013300.","journal-title":"J R Statis Soc Ser B (Methodol)"},{"key":"4093_CR46","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.21.633371","author":"DM Hazelaar","year":"2025","unstructured":"Hazelaar DM, Boers RG, Boers JB, et al. Improved circulating tumor DNA profiling by simultaneous extraction of DNA methylation and copy number information from Methylated DNA Sequencing data (MeD-seq). bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.01.21.633371.","journal-title":"bioRxiv"},{"issue":"4","key":"4093_CR47","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2014","unstructured":"Kr\u00e4mer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30(4):523\u201330. https:\/\/doi.org\/10.1093\/bioinformatics\/btt703.","journal-title":"Bioinformatics"},{"issue":"6","key":"4093_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060856","volume":"11","author":"K Anand","year":"2019","unstructured":"Anand K, Roszik J, Gombos D, et al. Pilot study of circulating tumor cells in early-stage and metastatic uveal melanoma. Cancers (Basel). 2019;11(6):856. https:\/\/doi.org\/10.3390\/cancers11060856.","journal-title":"Cancers (Basel)"},{"key":"4093_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.854253","volume":"12","author":"WD Zhou","year":"2022","unstructured":"Zhou WD, Shao L, Dong L, et al. Circulating microRNAs as quantitative biomarkers for diagnosis and prognosis of uveal melanoma. Front Oncol. 2022;12:854253. https:\/\/doi.org\/10.3389\/fonc.2022.854253.","journal-title":"Front Oncol"},{"issue":"4","key":"4093_CR50","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jtho.2020.12.011","volume":"16","author":"VK Lam","year":"2021","unstructured":"Lam VK, Zhang J, Wu CC, et al. Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC. J Thorac Oncol. 2021;16(4):601\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2020.12.011.","journal-title":"J Thorac Oncol"},{"issue":"13","key":"4093_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107830","volume":"31","author":"A Rostami","year":"2020","unstructured":"Rostami A, Lambie M, Yu CW, Stambolic V, Waldron JN, Bratman SV. Senescence, necrosis, and apoptosis govern circulating cell-free DNA release kinetics. Cell Rep. 2020;31(13):107830. https:\/\/doi.org\/10.1016\/j.celrep.2020.107830.","journal-title":"Cell Rep"},{"issue":"1","key":"4093_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46435-0","volume":"15","author":"KE Stanley","year":"2024","unstructured":"Stanley KE, Jatsenko T, Tuveri S, et al. Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology. Nat Commun. 2024;15(1):2220. https:\/\/doi.org\/10.1038\/s41467-024-46435-0.","journal-title":"Nat Commun"},{"issue":"1","key":"4093_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01585-8","volume":"15","author":"L Zhang","year":"2023","unstructured":"Zhang L, Li J. Unlocking the secrets: the power of methylation-based cfDNA detection of tissue damage in organ systems. Clin Epigenetics. 2023;15(1):168. https:\/\/doi.org\/10.1186\/s13148-023-01585-8.","journal-title":"Clin Epigenetics"},{"key":"4093_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.943253","volume":"12","author":"E Sanchez-Herrero","year":"2022","unstructured":"Sanchez-Herrero E, Serna-Blasco R, de Robado Lope L, Gonzalez-Rumayor V, Romero A, Provencio M. Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis. Front Oncol. 2022;12:943253. https:\/\/doi.org\/10.3389\/fonc.2022.943253.","journal-title":"Front Oncol"},{"issue":"10","key":"4093_CR55","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1158\/1541-7786.MCR-16-0044","volume":"14","author":"S Volik","year":"2016","unstructured":"Volik S, Alcaide M, Morin RD, Collins C. Cell-free DNA (cfDNA): clinical significance and utility in cancer shaped by emerging technologies. Mol Cancer Res Oct. 2016;14(10):898\u2013908. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0044.","journal-title":"Mol Cancer Res Oct."},{"issue":"5","key":"4093_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/biology12050738","volume":"12","author":"L Goesmann","year":"2023","unstructured":"Goesmann L, Refaian N, Bosch JJ, Heindl LM. Characterization and quantitation of the tumor microenvironment of uveal melanoma. Biology (Basel). 2023;12(5):738. https:\/\/doi.org\/10.3390\/biology12050738.","journal-title":"Biology (Basel)"},{"issue":"15","key":"4093_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152650","volume":"16","author":"E Lalonde","year":"2024","unstructured":"Lalonde E, Li D, Ewens K, Shields CL, Ganguly A. Genome-wide methylation patterns in primary uveal melanoma: development of MethylSig-UM, an epigenomic prognostic signature to improve patient stratification. Cancers (Basel). 2024;16(15):2650. https:\/\/doi.org\/10.3390\/cancers16152650.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4093_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00723-8","volume":"12","author":"CG Smith","year":"2020","unstructured":"Smith CG, Moser T, Mouliere F, et al. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. Genome Med. 2020;12(1):23. https:\/\/doi.org\/10.1186\/s13073-020-00723-8.","journal-title":"Genome Med"},{"issue":"5","key":"4093_CR59","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/annonc\/mdz075","volume":"30","author":"JH Lee","year":"2019","unstructured":"Lee JH, Saw RP, Thompson JF, et al. Pre-operative ctdna predicts survival in high-risk stage III cutaneous melanoma patients. Ann Oncol. 2019;30(5):815\u201322. https:\/\/doi.org\/10.1093\/annonc\/mdz075.","journal-title":"Ann Oncol"},{"issue":"5583","key":"4093_CR60","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1126\/science.1072047","volume":"297","author":"JA Bailey","year":"2002","unstructured":"Bailey JA, Gu Z, Clark RA. Recent segmental duplications in the human genome. Science. 2002;297(5583):1003\u20137. https:\/\/doi.org\/10.1126\/science.1072047.","journal-title":"Science"},{"issue":"6","key":"4093_CR61","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1101\/gr.gr-1871r","volume":"11","author":"JA Bailey","year":"2001","unstructured":"Bailey JA, Yavor AM, Massa HF, Trask BJ, Eichler EE. Segmental duplications: organization and impact within the current human genome project assembly. Genome Res. 2001;11(6):1005\u201317. https:\/\/doi.org\/10.1101\/gr.gr-1871r.","journal-title":"Genome Res"},{"issue":"2","key":"4093_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-016-2722-2","volume":"17","author":"G Stelzer","year":"2016","unstructured":"Stelzer G, Plaschkes I, Oz-Levi D, et al. VarElect: the phenotype-based variation prioritizer of the GeneCards Suite. BMC Genomics. 2016;17(2):444. https:\/\/doi.org\/10.1186\/s12864-016-2722-2.","journal-title":"BMC Genomics"},{"key":"4093_CR63","doi-asserted-by":"publisher","unstructured":"Fishilevich S, Nudel R, Rappaport N et al. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford).\u00a02017.\u00a0https:\/\/doi.org\/10.1093\/database\/bax028","DOI":"10.1093\/database\/bax028"},{"issue":"3","key":"4093_CR64","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acn3.51997","volume":"11","author":"LAA Giannini","year":"2024","unstructured":"Giannini LAA, Boers RG, van der Ende EL. <article-title update=\"added\">Distinctive cell\u2010free <scp>DNA<\/scp>methylation characterizes presymptomatic genetic frontotemporal dementia. Ann Clin Transl Neurol. 2024;11(3):744\u201356. https:\/\/doi.org\/10.1002\/acn3.51997.","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"4093_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051374","volume":"15","author":"MK Bos","year":"2023","unstructured":"Bos MK, Verhoeff SR, Oosting SF, et al. Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting. Cancers (Basel). 2023;15(5):1374. https:\/\/doi.org\/10.3390\/cancers15051374.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4093_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-023-00483-7","volume":"17","author":"S Siamoglou","year":"2023","unstructured":"Siamoglou S, Boers R, Koromina M, et al. Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response. Hum Genomics. 2023;17(1):37. https:\/\/doi.org\/10.1186\/s40246-023-00483-7.","journal-title":"Hum Genomics"},{"issue":"5","key":"4093_CR67","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.molmed.2024.03.007","volume":"30","author":"M Ezegbogu","year":"2024","unstructured":"Ezegbogu M, Wilkinson E, Reid G, et al. Cell-free DNA methylation in the clinical management of lung cancer. Trends Mol Med. 2024;30(5):499\u2013515. https:\/\/doi.org\/10.1016\/j.molmed.2024.03.007.","journal-title":"Trends Mol Med"},{"issue":"1","key":"4093_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-024-01646-6","volume":"16","author":"P Cui","year":"2024","unstructured":"Cui P, Zhou X, Xu S, et al. Prediction of methylation status using WGS data of plasma cfDNA for multi-cancer early detection (MCED). Clin Epigenetics. 2024;16(1):34. https:\/\/doi.org\/10.1186\/s13148-024-01646-6.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"4093_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01518-5","volume":"15","author":"Q Fang","year":"2023","unstructured":"Fang Q, Yuan Z, Hu H, Zhang W, Wang G, Wang X. Genome-wide discovery of circulating cell-free DNA methylation biomarkers for colorectal cancer detection. Clin Epigenetics. 2023;15(1):119. https:\/\/doi.org\/10.1186\/s13148-023-01518-5.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"4093_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01872-1","volume":"22","author":"SC Kim","year":"2023","unstructured":"Kim SC, Kim DW, Cho EJ. A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma. Mol Cancer. 2023;22(1):164. https:\/\/doi.org\/10.1186\/s12943-023-01872-1.","journal-title":"Mol Cancer"},{"issue":"1","key":"4093_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-024-01641-x","volume":"16","author":"Q Yang","year":"2024","unstructured":"Yang Q, Zhu X, Liu Y, et al. Reduced representative methylome profiling of cell-free DNA for breast cancer detection. Clin Epigenetics. 2024;16(1):33. https:\/\/doi.org\/10.1186\/s13148-024-01641-x.","journal-title":"Clin Epigenetics"},{"key":"4093_CR72","doi-asserted-by":"publisher","first-page":"1099071","DOI":"10.3389\/fimmu.2023.1099071","volume":"14","author":"W Wang","year":"2023","unstructured":"Wang W, Zhao H, Wang S. Identification of a novel immune-related gene signature for prognosis and the tumor microenvironment in patients with uveal melanoma combining single-cell and bulk sequencing data. Front Immunol. 2023;14:1099071. https:\/\/doi.org\/10.3389\/fimmu.2023.1099071.","journal-title":"Front Immunol"},{"issue":"1","key":"4093_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-00945-x","volume":"15","author":"X Liang","year":"2024","unstructured":"Liang X, Huang X, Cai Z, et al. The S100 family is a prognostic biomarker and correlated with immune cell infiltration in pan-cancer. Discov Oncol. 2024;15(1):137. https:\/\/doi.org\/10.1007\/s12672-024-00945-x.","journal-title":"Discov Oncol"},{"issue":"1","key":"4093_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00182-2","volume":"5","author":"YZ Beigi","year":"2024","unstructured":"Beigi YZ, Lanjanian H, Fayazi R, et al. Heterogeneity and molecular landscape of melanoma: implications for targeted therapy. Mol Biomed. 2024;5(1):17. https:\/\/doi.org\/10.1186\/s43556-024-00182-2.","journal-title":"Mol Biomed"},{"issue":"2","key":"4093_CR75","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1134\/S0026893324020183","volume":"58","author":"MV Zhilnikova","year":"2024","unstructured":"Zhilnikova MV, Troitskaya OS, Novak DD, Atamanov VV, Koval OA. [Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches]. Mol Biol (Mosk). 2024;58(2):189\u2013203.","journal-title":"Mol Biol (Mosk)"},{"key":"4093_CR76","doi-asserted-by":"publisher","first-page":"744300","DOI":"10.3389\/fimmu.2021.744300","volume":"12","author":"S Saito","year":"2021","unstructured":"Saito S, Cao DY, Victor AR, Peng Z, Wu HY, Okwan-Duodu D. RASAL3 is a putative RasGAP modulating inflammatory response by neutrophils. Front Immunol. 2021;12:744300. https:\/\/doi.org\/10.3389\/fimmu.2021.744300.","journal-title":"Front Immunol"},{"issue":"11","key":"4093_CR77","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.it.2023.09.002","volume":"44","author":"KH Johansen","year":"2023","unstructured":"Johansen KH, Golec DP, Okkenhaug K, Schwartzberg PL. Mind the GAP: RASA2 and RASA3 GTPase-activating proteins as gatekeepers of T cell activation and adhesion. Trends Immunol Nov. 2023;44(11):917\u201331. https:\/\/doi.org\/10.1016\/j.it.2023.09.002.","journal-title":"Trends Immunol Nov"},{"key":"4093_CR78","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jbior.2014.09.006","volume":"57","author":"S Schurmans","year":"2015","unstructured":"Schurmans S, Polizzi S, Scoumanne A, Sayyed S, Molina-Ortiz P. <article-title update=\"added\">The Ras\/Rap GTPase activating protein RASA3: from gene structure to in\u00a0vivo functions. Adv Biol Regul. 2015;57:153\u201361. https:\/\/doi.org\/10.1016\/j.jbior.2014.09.006.","journal-title":"Adv Biol Regul"},{"key":"4093_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2022.103302","volume":"112","author":"S Keane","year":"2022","unstructured":"Keane S, de Weerd HA, Ejeskar K. Dlg2 impairs dsDNA break repair and maintains genome integrity in neuroblastoma. DNA Repair. 2022;112:103302. https:\/\/doi.org\/10.1016\/j.dnarep.2022.103302.","journal-title":"DNA Repair"},{"issue":"2","key":"4093_CR80","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41388-018-0444-4","volume":"38","author":"YW Shao","year":"2019","unstructured":"Shao YW, Wood GA, Lu J, et al. Cross-species genomics identifies DLG2 as a tumor suppressor in osteosarcoma. Oncogene. 2019;38(2):291\u20138. https:\/\/doi.org\/10.1038\/s41388-018-0444-4.","journal-title":"Oncogene"},{"issue":"1","key":"4093_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00949-4","volume":"13","author":"J Yuan","year":"2020","unstructured":"Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13(1):113. https:\/\/doi.org\/10.1186\/s13045-020-00949-4.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4093_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03374-y","volume":"44","author":"RJ Nell","year":"2025","unstructured":"Nell RJ, Versluis M, Menger NV, et al. Digital PCR-based genetic profiling from vitreous fluid as liquid biopsy for primary uveal melanoma: a proof-of-concept study. J Exp Clin Cancer Res. 2025;44(1):124. https:\/\/doi.org\/10.1186\/s13046-025-03374-y.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-04093-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-04093-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-04093-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:38:52Z","timestamp":1768390732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-025-04093-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4093"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-04093-2","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adheres to the tenets of the Declaration of Helsinki and has been approved by the Erasmus MC medical ethics committee (MEC-2009-375), Human Research Ethics Committee protocols of Edith Cowan University (No. 11543 and No. 18957) and Sir Charles Gardner Hospital (No. 2013\u2009\u2212\u2009246 and No. RGS0000003289), Western Australia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.G. Boers, J. Boers, J. Gribnau and W.F.J. van IJcken are shareholders of Methylomics BV. All the other authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}